Dendritic cell activating vaccine adjuvants differ in the ability to elicit anti-tumor immunity due to an adjuvant specific induction of immune suppressive cells

摘要

PurposeWe questioned whether the vaccine adjuvant combination of TLR7 ligand agonist, imiquimod, with GM-CSF would result in enhanced dendritic cell recruitment and activation with increased antigen-specific immunity as compared with either adjuvant used alone.